drugset / Trial / NCT02482077
Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of Sofosbuvir containing regimens in treatment-naive or treatment-experienced patients with HCV genotypes 2 infection.
Timeline
- Start
- 2015-01
- Primary completion
- 2017-12-31
- Completion
- 2018-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daclatasvir | Small molecule | 60 mg | — |
| Subject | LDV/SOF | Unknown | 90 mg | Oral |
| Subject | LDV/SOF | Unknown | 400 mg | Oral |
| Subject | Ribavirin | Small molecule | 1000 mg | Oral |
| Subject | Ribavirin | Small molecule | 1200 mg | Oral |
| Subject | Sofosbuvir | Small molecule | 400 mg | Oral |